Actuate Therapeutics

Capital has funded clinical development and public listings rather than producing returns yet. 2025 operating cash outflow was about 19.2 million dollars, and Q1‑26 outflow was 5.0 million dollars.

General and administrative expense rose in 2025 largely from stock‑based compensation and public‑company costs, and the company raised equity via a 2025 public offering, private placement, committed equity facility, and ATM.

We recognize that development‑stage biotech must invest ahead of revenue, but dilution and limited runway weigh on this score.